Pharmacokinetics of buprenorphine after intravenous administration in the mouse

Journal of the American Association for Laboratory Animal Science

Volumn 45, Issue 3, 2006, Pages 12-16

  Yu, Shipeng ^a   Zhang, Xiaofeng ^a   Sun, Yichun ^a   Peng, Yingxu ^a   Johnson, James ^a   Mandrell, Tim ^b   Shukla, Atul J ^a   Laizure, S Casey ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; STEADY STATE; TANDEM MASS SPECTROMETRY;

ANALGESICS, OPIOID; ANIMALS; AREA UNDER CURVE; BUPRENORPHINE; FEMALE; HALF-LIFE; INJECTIONS, INTRAVENOUS; MICE; MOLECULAR STRUCTURE;

ANIMALIA;

EID: 33744792920     PISSN: 15596109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Akaike H. 1974. A new look at the statistical model identification. IEEE Transactions on Automatic Control AC 19:716-723.
2. Beauverie P, Khan E, Ghaleh B, van de Vyver M, Poisson N, Jacquot C. 1994. [Comparative pharmacodynamics of methadone, buprenorphine, and codeine. Article in French] Ann Med Interne (Paris) 145(3 Suppl):15-18.
3. Blom Y, Bondesson U, Anggard E. 1985. Analysis of buprenorphine and its N-dealkylated metabolite in plasma and urine by selected-ion monitoring. J Chromatogr 338:89-98.
4. Boas RA, Villiger JW. 1985. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth 57:192-196.
5. Brewster D, Humphrey MJ, McLeavy MA. 1981. The systemic bioavailability of buprenorphine by various routes of administration. J Pharm Pharmacol 33:500-506.
6. Christoph T, Kogel B, Schiene K, Meen M, De Vry J, Friderichs E. 2005. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharm 507:87-98.
7. Cowan A. 1995. Update on the general pharmacology of buprenorphine. In: Cowan A, Lewis JW, editors. Buprenorphine: combating drug abuse with a unique opioid. New York: Wiley-Liss Press. p 326-350
8. Cowan A, Doxey JC, Harry EJ. 1977. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 60:547-554.
9. Cowan A, Lewis JW, Macfarlane IR. 1977. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537-545.
10. Everhart ET, Cheung P, Shwonek P, Zabel K, Tisdale EC, Jacob P 3rd, Mendelson J, Jones RT. 1997. Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: application to pharmacokinetics of sublingual buprenorphine. Clin Chem 43:2292-2302.
11. Gades NM, Danneman PJ, Wixson SK, Tolley EA. 2000. The magnitude and duration of the analgesic effect of morphine, butorphanol, and buprenorphine in rats and mice. Contemp Top Lab Anim Sci 39(2):8-13.
12. Garrett ER, Chandran VR. 1985 Pharmacokinetics of morphine and its surrogates VI: bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine. J Pharm Sci 74:515-524.
13. Gopal S. 2000. Pharmacokinetic/pharmacodynamic investigation of the mechanism of the bell-shaped dose analgesic effect curve of buprenorphine in rats: antagonism by the metabolite [PhD dissertation]. Philadelphia: Temple University. p 257.
14. Harris DS, Mendelson JE, Lin ET, Upton RA, Jones RT. 2004. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet 43:329-340.
15. Ho ST, Wang JJ, Ho W, Hu OY. 1991. Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. J Chromatogr 570:339-350.
16. Huang P, Kehner GB, Cowan A, Liu-Chen LY. 2001. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688-695.
17. Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. 1997. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 60:1953-1964.
18. Kay B. 1978. A double-blind comparison of morphine and buprenorphine in the prevention of pain after operation. Br J Anaesth 50:605-609.
19. Kuhlman JJ Jr, Lalani S, Magluilo J Jr, Levine B, Darwin WD. 1996. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 20:369-378.
20. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D. 1998. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93:475-486.
21. Ling W, Wesson DR. 2003. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend 70(2 Suppl):S49-S57.
22. Ling W, Wesson DR, Charuvastra C, Klett CJ. 1996. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatr 53:401-407.
23. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, Evans CJ. 2003. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 23:10331-10337.
24. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. 1976. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517-532.
25. McAleer SD, Mills RJ, Polack T, Hussain T, Rolan PE, Gibbs AD, Mullins FG, Hussein Z. 2003. Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naive healthy male volunteers under a naltrexone block. Drug Alcohol Depend 72:75-83.
26. McQuay HJ, Moore RA. 1995. Buprenorphine kinetics in humans. In: Cowan A, Lewis J, editors. Buprenorphine: combating drug abuse with a unique opioid. New York: Wiley-Liss Press. p 137-150.
27. National Research Council. 1996. Guide for the care and use of laboratory animals. Washington (DC): National Academy Press.
28. Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T. 1997. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 281:428-433.
29. Ohtani M, Kotaki H, Sawada Y, Iga T. 1995. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 272:505-510.
30. Ohtani M, Kotaki H, Uchino K, Sawada Y, Iga T. 1994. Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. Drug Metab Dispos 22:2-7.
31. Olkkola KT, Maunuksela EL, Korpela R. 1989. Pharmacokinetics of intravenous buprenorphine in children. Br J Clin Pharmacol 28:202-204.
32. Richards ML, Sadee W. 1985. Buprenorphine is an antagonist at the kappa opioid receptor. Pharm Res 2:178-181.
33. Rothman RB, Ni Q, Xu H. 1995. Buprenorphine: a review of the binding literature, In: Cowan A, Lewis JW, editors. Buprenorphine: combatting drug abuse with a unique opioid. New York: Wiley-Liss Press. p 21.
34. Yassen A, Olofsen E, Dahan A, Danhof M. 2005. Pharmacokinetic- pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther 313:1136-1149.
35. Yue H, Borenstein RB, Jansen SA, Raffa RB. 2005. Liquid chromatography-mass spectrometric analysis of buprenorphine and its N-dealkylated metabolite norbuprenorphine in rat brain tissue and plasma. J Pharmacol Toxicol Methods Forthcoming.